eXoZymes Inc. completed an underwritten public offering of 330,575 units at $8.99 per share, raising approximately $5.95 million in gross proceeds before expenses. The company plans to use net proceeds for development of its NCT product candidate, advancing other product opportunities, and general corporate purposes.